Brokerages Set Alamar Biosciences, Inc. (NASDAQ:ALMR) PT at $30.00

Alamar Biosciences, Inc. (NASDAQ:ALMR) has been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $30.00.

Several equities research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Alamar Biosciences to a “hold” rating in a report on Saturday, April 25th. Stifel Nicolaus assumed coverage on shares of Alamar Biosciences in a report on Tuesday, May 12th. They issued a “buy” rating and a $28.00 target price on the stock. Zacks Research upgraded shares of Alamar Biosciences to a “hold” rating in a report on Wednesday, May 13th. TD Cowen assumed coverage on shares of Alamar Biosciences in a report on Tuesday, May 12th. They issued a “buy” rating and a $30.00 target price on the stock. Finally, Leerink Partners assumed coverage on shares of Alamar Biosciences in a report on Tuesday, May 12th. They issued an “outperform” rating and a $35.00 target price on the stock.

Alamar Biosciences Stock Down 3.2%

Alamar Biosciences stock opened at $20.86 on Tuesday. Alamar Biosciences has a 12 month low of $20.40 and a 12 month high of $27.20.

Alamar Biosciences (NASDAQ:ALMR) last posted its earnings results on Friday, May 8th. The company reported ($1.74) EPS for the quarter. The business had revenue of $26.04 million during the quarter.

Insider Activity at Alamar Biosciences

In related news, major shareholder Innovation Fund Gp Illumina II bought 235,294 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The shares were bought at an average price of $17.00 per share, for a total transaction of $3,999,998.00. Following the completion of the acquisition, the insider owned 507,076 shares of the company’s stock, valued at $8,620,292. This trade represents a 86.57% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Nicholas Naclerio bought 235,294 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The stock was bought at an average price of $17.00 per share, for a total transaction of $3,999,998.00. Following the acquisition, the director directly owned 507,076 shares of the company’s stock, valued at $8,620,292. The trade was a 86.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

About Alamar Biosciences

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.